Startup profile for Unisound: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Unisound funding, valuation and investors

Chinese voice-AI and conversational intelligence for healthcare, IoT, and enterprise.

Keep track of Unisound

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public · Beijing, China

Source links not recorded Last verified: 2026-07-25

Overview

Unisound (云知声) develops automatic speech recognition, natural language understanding, and voice-interaction platforms for healthcare, smart devices, and enterprise customers in China. The company provides voice-AI chips, cloud services, and industry-specific solutions including medical documentation and IoT voice control. Founded in Beijing, Unisound raised from Qiming Venture Partners, Qualcomm Ventures, and others before listing on the Hong Kong Stock Exchange in June 2025 at HK$205 per share. Andreessen Horowitz appears on the company's public investor list.

Why Unisound is interesting

A decade of China-focused speech-AI commercialization culminated in a June 2025 Hong Kong IPO (9678.HK) — one of the few voice-AI vendors to reach public markets in the region.

Product & use cases

Unisound offers end-to-end voice-AI: ASR, NLP, TTS, and domain-specific models for healthcare (clinical voice documentation), automotive, and smart-home IoT. The company also designs voice-AI semiconductors and sells cloud API access to enterprise developers in China.

  • Medical voice documentation and clinical assistant workflows in Chinese hospitals
  • Smart speaker and IoT device voice control for consumer electronics OEMs
  • Enterprise call-center and customer-service automation in Mandarin

Key facts

  • IPO (Jun 2025): listed on Hong Kong Stock Exchange (9678.HK) at HK$205/share — PR Newswire
  • Prior rounds included Qiming Venture Partners and Qualcomm Ventures per press
  • 10+ years of Mandarin voice-AI for healthcare and IoT in China

Funding history (newest first)

IPO

2025-06 Not disclosed (HK listing)
  • Public markets

Source: https://www.prnewswire.com/news-releases/unisound-hong-kong-ipo

Investors in our directory

Funds linked from Unisound's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Competitive landscape

Edge: Unisound built deep Mandarin speech models and healthcare vertical integrations over 10+ years in China — a data and deployment moat that global players (Google, Amazon Alexa) cannot easily replicate in regulated Chinese healthcare.

Chinese voice-AI is a two-tier market: platform giants (Baidu, Alibaba, Tencent) and specialists (iFLYTEK, Unisound). Unisound differentiated on healthcare and custom silicon but faced intense price competition. The 2025 HK IPO provides public-market capital for R&D; profitability and margin vs. iFLYTEK remain key investor questions. a16z's presence reflects cross-border portfolio exposure rather than operational U.S. overlap.

  • iFLYTEK direct

    Larger Chinese speech-AI incumbent with broader government and education contracts; Unisound competes on healthcare and IoT niches.

  • Baidu incumbent

    DuerOS and Baidu speech cloud; platform scale advantage vs. Unisound's vertical focus.

  • Nuance (Microsoft) adjacent

    Global clinical documentation leader; limited China footprint compared to Unisound's local healthcare integrations.

Notable stories

  • Unisound went public on the Hong Kong Stock Exchange in June 2025 after more than a decade building speech-AI for Chinese healthcare and smart devices (PR Newswire).
  • The company developed proprietary voice-AI chips alongside cloud services — a full-stack approach uncommon among pure software speech vendors (company materials).

Industries

AI & Machine Learning Healthtech Enterprise SaaS

Market / IPO context

Ticker: 9678.HK (Hong Kong Stock Exchange)

IPO status: public

IPO date: 2025-06

Editorial / static context — not a live quote.

Related funding articles

Venture Capital Tracker pieces that cover Unisound's financing or category context.

FAQs about Unisound

Practical answers founders, operators, and investors typically search for.

Unisound is a Chinese voice-AI company providing speech recognition, NLP, and voice-interaction platforms for healthcare, IoT, and enterprise customers, primarily in Mandarin.
Yes. Unisound listed on the Hong Kong Stock Exchange in June 2025 under ticker 9678.HK.
Andreessen Horowitz appears on Unisound's investor list. Prior institutional backers reported in press include Qiming Venture Partners and Qualcomm Ventures.
Unisound is headquartered in Beijing, China, and serves primarily Chinese enterprise and healthcare markets.
Both are Chinese speech-AI specialists. iFLYTEK is larger with broader government and education reach; Unisound emphasizes healthcare documentation and IoT voice chips.
Healthcare (clinical voice documentation), smart devices/IoT, automotive voice, and enterprise customer service — primarily in China.
Unisound completed its Hong Kong IPO in June 2025 at HK$205 per share per press coverage.
Unisound's core business and customers are in China. U.S. investor exposure (a16z) does not indicate a primary U.S. commercial footprint.
Unisound trades on the Hong Kong Stock Exchange as 9678.HK.
Public filing details should be consulted post-IPO. Pre-IPO Chinese voice-AI vendors often traded growth for market share; profitability is an investor focus after listing.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.